[1] PRABHU P, NITISH K R, KOLAND M, et al. Preparation and evaluation of nano-vesicles of brimonidine tartrate as an ocular drug delivery system [J]. J Young Pharm, 2010, 2(4): 356-361.
[2] ABDELKADER H, ISMAIL S, KAMAL A, et al.Design and evaluation of controlled-release niosomes and discomes for naltrexone hydrochloride ocular delivery [J]. J Pharm Sci, 2011, 100(5): 1833-1846.
[3] NAGARWAL R C, SINGH P N, KANT S, et al. Chitosan coated PLA nanoparticles for ophthalmic delivery: characterization, in-vitro and in-vivo study in rabbit eye [J]. J Biomed Nanotechnol, 2010, 6(6): 648-657.
[4] NAGARWAL R C, SINGH P N, KANT S, et al. Chitosan nanoparticles of 5-fluorouracil for ophthalmic delivery: characterization, in-vitro and in-vivo study [J]. Chem Pharm Bull (Tokyo), 2011, 59(2): 272-278.
[5] ZHU J, JIANG F, YAN H, et al. Preparation and evaluation of pilocarpine nitrate in situ gel for ophthalmic use [J]. Chin Tradit Herb Drugs (中草药), 2010, 41(5): 720-724.
[6] DURAND M, POURCHEZ J, LOUIS B, et al. Plastinated nasal model: a new concept of anatomically realistic cast [J]. Rhinology, 2011, 49(1):30-36.
[7] MCINNES F, BAILLIE A J, STEVENS H N. The use of simple dynamic mucosal models and confocal microscopy for the evaluation of lyophilised nasal formulations[J]. J Pharm Pharmacol, 2007, 59(6): 759-767.
[8] SINGH V, BUSHETTI S S, APPALA R, et al. Stimuli-sensitive hydrogels: a novel ophthalmic drug delivery system [J]. Indian J Ophthalmol, 2010, 58(6):477-481.
[9] AL-GHANANEEM A M, MALKAWI A H, CROOKS P A. Bioavailability of Δ9-tetrahydrocannabinol following intranasal administration of a mucoadhesive gel spray delivery system in conscious rabbits [J]. Drug Dev Ind Pharm, 2011, 37(3): 329-334.
[10] NIE S, HSIAO W W, PAN W, et al. Thermoreversible Pluronic F127-based hydrogel containing liposomes for the controlled delivery of paclitaxel: in vitro drug release, cell cytotoxicity, and uptake studies [J]. Int J Nanomedicine, 2011, 6: 151-166.
[11] CHRISTENSEN D, FOGED C, ROSENKRANDS I, et al. CAF01 liposomes as a mucosal vaccine adjuvant: In vitro and in vivo investigation [J]. Int J Pharm, 2010, 390(1):19-24.
[12] KRTI L, KIS L, VESZELKA S, et al. A model for studying nasal drug delivery: RPMI 2650 human nasal epithelial cell line [J]. Sci Pharm, 2010, 78: 579.
[13] WENGST A, REICHI S. RPMI 2650 epithelial model and three-dimensional reconstructed human nasal mucosa as in vitro models for nasal permeation studies [J]. Eur J Pharm Biopharm, 2010, 74(2): 290-297.
[14] CHO H J, TERMSARASAB U, KIM J S, et al. In vitro nasal cell culture systems for drug transport studies [J]. J Pharm Invest, 2010, 40(6): 321-332.
[15] CUI C Y, CUI G H, ZHAO M. Model and mechanism of the insulin transport across human immortalized oral epithelial cell monolayers [J]. J Cap Med Univ (首都医科大学学报), 2008, 29(3)：327-331.
[16] HIROSHIMA Y, BANDO M, KATAOKA M, et al. Shosaikoto increases calprotectin expression in human oral epithelial cells [J]. J Periodontal Res, 2010, 45(1): 79-86.
[17] SMISTAD G, JACOBSEN J, SAN DE S A. Multivariate toxicity screening of liposomal formulations on a human buccal cell line [J]. Int J Pharm, 2007, 330(1-2): 14-22.
[18] WANG Y, ZUO Z, CHOW M S. HO-1-u-1 model for screening sublingual drug delivery--influence of pH, osmolarity and permeation enhancer [J]. Int J Pharm, 2009, 370(1-2): 68-74.
[19] CONTRERAS-RUIZ L, DE LA FUENTE M, PRRAGA J E, et al. Intracellular trafficking of hyaluronic acid-chitosan oligomer-based nanoparticles in cultured human ocular surface cells [J]. Mol Vis, 2011, 17: 279-290.
[20] MIAO X Q, CHEN J, WU J, et al. Culture and cryopreservation of rabbit con junctival epithelial cells and fibroblasts [J]. Guangdong Med J (广东医学), 2009, 30(2): 171-173.
[21] WANG S, ZHANG J, JIANG T, et al. Protective effect of Coenzyme Q(10) against oxidative damage in human lens epithelial cells by novel ocular drug carriers [J]. Int J Pharm, 2011, 403(1-2): 219-229.
[22] CHAI G B, PAN Y F, LI F Z. Effect of borneol/mentholum eutectic mixture on nasal-brain delivery of neurotoxin loaded nanoparticles [J]. China J Chin Mater Med (中国中药杂志), 2009, 34(6): 698-701.
[23] LIU L, ZHAO Y M, LI F Z. Brain pharmacokinetics of self-assembled neurotoxin-loaded nanoparticles after intranasal administration in rats [J]. Chin Pharm J (中国药学杂志), 2011, 46(3): 203-207.
[24] LIU R, LIU Z, ZHANG C, et al. Gelucire44/14 as a novel absorption enhancer for drugs with different hydrophilicities: In vitro and in vivo improvement on transcorneal permeation [J]. J Pharm Sci, 2011, 100(8): 3186-3195.
[25] LIU Z, ZHANG X, WU H, et al. Preparation and evaluation of solid lipid nanoparticles of baicalin for ocular drug delivery system in vitro and in vivo [J]. Drug Dev Ind Pharm, 2011, 37(4): 475-481.
[26] WEN Z, YAN Z, HU K, et al. Odorranalectin-conjugated nanoparticles: Preparation, brain delivery and pharmacodynamic study on Parkinson's disease following intranasal administration [J]. J Controlled Release, 2011, 151(2): 131-138.
[27] PANDEY R S, BABBAR A K, KAUL A, et al. Evaluation of ISCOM matrices clearance from rabbit nasal cavity by gamma scintigraphy [J]. Int J Pharm, 2010, 398(1-2): 231-236.
[28] WU H, LIU Z, PENG J, et al. Design and evaluation of baicalin-containing in situ pH-triggered gelling system for sustained ophthalmic drug delivery [J]. Int J Pharm, 2011, 410(1-2): 31-40.
[29] KOMPELLA U B, KADAM R S, LEE V H.Recent advances in ophthalmic drug delivery [J]. Ther Deliv, 2010, 1(3): 435-456.
[30] SHEN J, DENG Y, JIN X, et al. Thiolated nanostructured lipid carriers as a potential ocular drug delivery system for cyclosporine A: Improving in vivo ocular distribution [J]. Int J Pharm, 2010, 402(1-2): 248-253.